Inozyme Pharma Inc (NASDAQ: INZY) is -41.78% lower on its value in year-to-date trading and has touched a low of $2.55 and a high of $7.80 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The INZY stock was last observed hovering at around $2.69 in the last trading session, with the day’s loss setting it -0.21%.
Currently trading at $2.48, the stock is -19.04% and -40.87% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.8 million and changing -7.81% at the moment leaves the stock -50.03% off its SMA200. INZY registered -35.75% loss for a year compared to 6-month loss of -48.44%. The firm has a 50-day simple moving average (SMA 50) of $4.2475 and a 200-day simple moving average (SMA200) of $4.978975.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -39.07% gain in the last 1 month and extending the period to 3 months gives it a -50.20%, and is -8.82% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.19% over the week and 7.71% over the month.
Inozyme Pharma Inc (INZY) has around 59 employees, a market worth around $159.32M and $0.00M in sales. Distance from 52-week low is -2.75% and -68.18% from its 52-week high. The company has generated returns on investments over the last 12 months (-77.18%).
The EPS is expected to shrink by -16.46% this year
127.0 institutions hold shares in Inozyme Pharma Inc (INZY), with institutional investors hold 97.16% of the company’s shares. The shares outstanding are 64.18M, and float is at 43.50M with Short Float at 7.62%. Institutions hold 96.67% of the Float.
The top institutional shareholder in the company is ADAGE CAPITAL PARTNERS GP, L.L.C. with over 5.73 million shares valued at $25.55 million. The investor’s holdings represent 9.2742 of the INZY Shares outstanding. As of 2024-06-30, the second largest holder is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC with 4.49 million shares valued at $20.05 million to account for 7.2765 of the shares outstanding. The other top investors are SOFINNOVA INVESTMENTS, INC. which holds 4.28 million shares representing 6.9292 and valued at over $19.09 million, while EVENTIDE ASSET MANAGEMENT, LLC holds 6.3721 of the shares totaling 3.94 million with a market value of $17.56 million.
Inozyme Pharma Inc (INZY) Insider Activity
The most recent transaction is an insider sale by Treco Douglas A, the company’s CEO. SEC filings show that Treco Douglas A sold 7,523 shares of the company’s common stock on Apr 02 ’24 at a price of $6.94 per share for a total of $52210.0. Following the sale, the insider now owns 20665.0 shares.
